Literature DB >> 14647275

Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis.

George Papanikolaou1, Mark E Samuels, Erwin H Ludwig, Marcia L E MacDonald, Patrick L Franchini, Marie-Pierre Dubé, Lisa Andres, Julie MacFarlane, Nikos Sakellaropoulos, Marianna Politou, Elizabeta Nemeth, Jay Thompson, Jenni K Risler, Catherine Zaborowska, Ryan Babakaiff, Christopher C Radomski, Terry D Pape, Owen Davidas, John Christakis, Pierre Brissot, Gillian Lockitch, Tomas Ganz, Michael R Hayden, Y Paul Goldberg.   

Abstract

Juvenile hemochromatosis is an early-onset autosomal recessive disorder of iron overload resulting in cardiomyopathy, diabetes and hypogonadism that presents in the teens and early 20s (refs. 1,2). Juvenile hemochromatosis has previously been linked to the centromeric region of chromosome 1q (refs. 3-6), a region that is incomplete in the human genome assembly. Here we report the positional cloning of the locus associated with juvenile hemochromatosis and the identification of a new gene crucial to iron metabolism. We finely mapped the recombinant interval in families of Greek descent and identified multiple deleterious mutations in a transcription unit of previously unknown function (LOC148738), now called HFE2, whose protein product we call hemojuvelin. Analysis of Greek, Canadian and French families indicated that one mutation, the amino acid substitution G320V, was observed in all three populations and accounted for two-thirds of the mutations found. HFE2 transcript expression was restricted to liver, heart and skeletal muscle, similar to that of hepcidin, a key protein implicated in iron metabolism. Urinary hepcidin levels were depressed in individuals with juvenile hemochromatosis, suggesting that hemojuvelin is probably not the hepcidin receptor. Rather, HFE2 seems to modulate hepcidin expression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14647275     DOI: 10.1038/ng1274

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  280 in total

Review 1.  The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  Measurement of serum hepcidin-25 levels as a potential test for diagnosing hemochromatosis and related disorders.

Authors:  Yoshibumi Kaneko; Hiroaki Miyajima; Alberto Piperno; Naohisa Tomosugi; Hisao Hayashi; Natsuko Morotomi; Ken-ichi Tsuchida; Takaaki Ikeda; Akihisa Ishikawa; Yusuke Ota; Shinya Wakusawa; Kentaro Yoshioka; Satoshi Kono; Sara Pelucchi; Ai Hattori; Yasuaki Tatsumi; Toshihide Okada; Masakazu Yamagishi
Journal:  J Gastroenterol       Date:  2010-06-09       Impact factor: 7.527

3.  Soluble repulsive guidance molecule c/hemojuvelin is a broad spectrum bone morphogenetic protein (BMP) antagonist and inhibits both BMP2- and BMP6-mediated signaling and gene expression.

Authors:  Mahta Nili; Ujwal Shinde; Peter Rotwein
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

Review 4.  Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation.

Authors:  Chia Chi Sun; Valentina Vaja; Jodie L Babitt; Herbert Y Lin
Journal:  Am J Hematol       Date:  2012-01-31       Impact factor: 10.047

Review 5.  Iron homeostasis and the inflammatory response.

Authors:  Marianne Wessling-Resnick
Journal:  Annu Rev Nutr       Date:  2010-08-21       Impact factor: 11.848

6.  Novel tools for the evaluation of iron metabolism.

Authors:  Léon Kautz; Elizabeta Nemeth
Journal:  Haematologica       Date:  2010-12       Impact factor: 9.941

Review 7.  Murine mutants in the study of systemic iron metabolism and its disorders: an update on recent advances.

Authors:  Thomas B Bartnikas; Mark D Fleming; Paul J Schmidt
Journal:  Biochim Biophys Acta       Date:  2012-01-28

Review 8.  Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches.

Authors:  Paul J Schmidt; Mark D Fleming
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

9.  Two middle-age-onset hemochromatosis patients with heterozygous mutations in the hemojuvelin gene in a Chinese family.

Authors:  Shufeng Li; Jun Xue; Baojun Chen; Qiwei Wang; Minke Shi; Xiaojing Xie; Liang Zhang
Journal:  Int J Hematol       Date:  2014-03-02       Impact factor: 2.490

10.  Transferrin receptor 2 protein is not expressed in normal erythroid cells.

Authors:  Alessia Calzolari; Silvia Deaglio; Nadia Maria Sposi; Eleonora Petrucci; Ornella Morsilli; Marco Gabbianelli; Fabio Malavasi; Cesare Peschle; Ugo Testa
Journal:  Biochem J       Date:  2004-08-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.